Pillar Pacific Capital Management LLC Has $5.76 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)


Share on StockTwits

Pillar Pacific Capital Management LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,868 shares of the biopharmaceutical company’s stock after selling 312 shares during the quarter. Pillar Pacific Capital Management LLC’s holdings in Gilead Sciences were worth $5,760,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Premier Fund Managers Ltd boosted its holdings in shares of Gilead Sciences by 10.0% during the fourth quarter. Premier Fund Managers Ltd now owns 20,204 shares of the biopharmaceutical company’s stock worth $1,144,000 after purchasing an additional 1,843 shares during the period. CI Investments Inc. boosted its holdings in shares of Gilead Sciences by 1.2% during the fourth quarter. CI Investments Inc. now owns 382,421 shares of the biopharmaceutical company’s stock worth $22,280,000 after purchasing an additional 4,610 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Gilead Sciences by 5.3% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 375,882 shares of the biopharmaceutical company’s stock worth $21,899,000 after purchasing an additional 18,906 shares during the period. ProShare Advisors LLC lifted its stake in Gilead Sciences by 15.7% in the fourth quarter. ProShare Advisors LLC now owns 1,415,654 shares of the biopharmaceutical company’s stock valued at $82,476,000 after acquiring an additional 191,724 shares during the last quarter. Finally, Profund Advisors LLC lifted its stake in Gilead Sciences by 8.2% in the fourth quarter. Profund Advisors LLC now owns 340,458 shares of the biopharmaceutical company’s stock valued at $19,835,000 after acquiring an additional 25,718 shares during the last quarter. Institutional investors own 76.36% of the company’s stock.

In other news, EVP Brett A. Pletcher sold 1,975 shares of the stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total value of $133,134.75. Following the completion of the sale, the executive vice president now owns 28,832 shares of the company’s stock, valued at approximately $1,943,565.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.13% of the company’s stock.

GILD has been the topic of a number of recent analyst reports. Barclays dropped their price target on shares of Gilead Sciences from $67.00 to $62.00 in a research report on Thursday, October 29th. Guggenheim raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Monday, January 4th. Smith Barney Citigroup dropped their price target on shares of Gilead Sciences from $75.00 to $72.00 in a research report on Tuesday, December 22nd. Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Finally, Robert W. Baird boosted their target price on shares of Gilead Sciences from $63.00 to $67.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 16th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $94.93.

NASDAQ:GILD traded down $0.83 during trading hours on Tuesday, reaching $63.28. 340,146 shares of the stock were exchanged, compared to its average volume of 8,977,984. Gilead Sciences, Inc. has a twelve month low of $56.56 and a twelve month high of $85.97. The company has a debt-to-equity ratio of 1.65, a current ratio of 3.25 and a quick ratio of 3.15. The firm has a 50 day moving average of $65.08 and a 200 day moving average of $63.01. The stock has a market cap of $79.32 billion, a PE ratio of 66.09, a PEG ratio of 0.67 and a beta of 0.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $2.19 EPS for the quarter, beating the consensus estimate of $2.15 by $0.04. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.06 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 30th. Stockholders of record on Monday, March 15th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend is Friday, March 12th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.68. Gilead Sciences’s dividend payout ratio is presently 44.30%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: Benefits of owning preferred stock

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.